PMID- 30633164
OWN - NLM
STAT- MEDLINE
DCOM- 20190118
LR  - 20231005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 2
DP  - 2019 Jan
TI  - Qishenyiqi dripping pill improves ventricular remodeling and function in patients 
      with chronic heart failure: A pooled analysis.
PG  - e13906
LID - 10.1097/MD.0000000000013906 [doi]
LID - e13906
AB  - BACKGROUND: Qishenyiqi dripping pill for chronic heart failure (CHF) remains 
      controversial due to lack of high-quality trials. Therefore, we conduct this 
      pooled-analysis to evaluate the efficacy and safety of Qishenyiqi in CHF 
      patients. METHODS: We searched for randomized clinical trials for Qishenyiqi 
      dripping pill in treating CHF up to August 2018 through China National Knowledge 
      Infrastructure (CNKI), the PubMed Database, the Wanfang Database, the China 
      Scientific Journal Database (VIP), and the Chinese Biomedicine Literature Service 
      System. RevMan 5.3 was used for pooled analyses. Based on the New York Heart 
      Association (NYHA) classification, the clinical therapeutic effect was collected 
      as the primary endpoint. RESULTS: The efficacy and safety of Qishenyiqi combined 
      with routine treatment significantly increased NYHA functional classification, 
      left ventricular ejection fraction, cardiac index, and 6-minute walking test and 
      decreased brain natriuretic peptide, left ventricular end-diastolic, and 
      end-systolic dimensions with no obvious side effects in comparison with routine 
      therapy alone. CONCLUSIONS: Together these results provide important insights 
      into Qishenyiqi is effective and safe in improving ventricular remodeling and 
      function of CHF patients. PROSPERO REGISTRATION NUMBER: PROSPERO106695.
FAU - Chang, Mingzheng
AU  - Chang M
AD  - Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese 
      Ministry of Education, Chinese National Health Commission and Chinese Academy of 
      Medical Sciences, State and Shandong Province Joint Key Laboratory of 
      Translational Cardiovascular Medicine, Department of Cardiology, Shandong 
      University Qilu Hospital, School of Basic Medical Sciences of Shandong 
      University.
AD  - Department of Endocrinology & Metabolism, Shandong Provincial Qianfoshan 
      Hospital, Shandong University, Jinan, Shandong, China.
FAU - Cheng, Lei
AU  - Cheng L
AD  - Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese 
      Ministry of Education, Chinese National Health Commission and Chinese Academy of 
      Medical Sciences, State and Shandong Province Joint Key Laboratory of 
      Translational Cardiovascular Medicine, Department of Cardiology, Shandong 
      University Qilu Hospital, School of Basic Medical Sciences of Shandong 
      University.
AD  - Department of Endocrinology & Metabolism, Shandong Provincial Qianfoshan 
      Hospital, Shandong University, Jinan, Shandong, China.
FAU - Shen, Yaqian
AU  - Shen Y
AD  - Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese 
      Ministry of Education, Chinese National Health Commission and Chinese Academy of 
      Medical Sciences, State and Shandong Province Joint Key Laboratory of 
      Translational Cardiovascular Medicine, Department of Cardiology, Shandong 
      University Qilu Hospital, School of Basic Medical Sciences of Shandong 
      University.
AD  - Department of Endocrinology & Metabolism, Shandong Provincial Qianfoshan 
      Hospital, Shandong University, Jinan, Shandong, China.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese 
      Ministry of Education, Chinese National Health Commission and Chinese Academy of 
      Medical Sciences, State and Shandong Province Joint Key Laboratory of 
      Translational Cardiovascular Medicine, Department of Cardiology, Shandong 
      University Qilu Hospital, School of Basic Medical Sciences of Shandong 
      University.
AD  - Department of Endocrinology & Metabolism, Shandong Provincial Qianfoshan 
      Hospital, Shandong University, Jinan, Shandong, China.
FAU - Zhang, Zhongwen
AU  - Zhang Z
AD  - Department of Endocrinology & Metabolism, Shandong Provincial Qianfoshan 
      Hospital, Shandong University, Jinan, Shandong, China.
FAU - Hao, Panpan
AU  - Hao P
AD  - Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese 
      Ministry of Education, Chinese National Health Commission and Chinese Academy of 
      Medical Sciences, State and Shandong Province Joint Key Laboratory of 
      Translational Cardiovascular Medicine, Department of Cardiology, Shandong 
      University Qilu Hospital, School of Basic Medical Sciences of Shandong 
      University.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (qishen yiqi)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Chronic Disease
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Natriuretic Peptide, Brain/metabolism
MH  - Randomized Controlled Trials as Topic
MH  - Ventricular Function, Left/*drug effects
MH  - Ventricular Remodeling/*drug effects
PMC - PMC6336621
COIS- The authors declare that they have no competing interests.
EDAT- 2019/01/12 06:00
MHDA- 2019/01/19 06:00
PMCR- 2019/01/11
CRDT- 2019/01/12 06:00
PHST- 2019/01/12 06:00 [entrez]
PHST- 2019/01/12 06:00 [pubmed]
PHST- 2019/01/19 06:00 [medline]
PHST- 2019/01/11 00:00 [pmc-release]
AID - 00005792-201901110-00015 [pii]
AID - MD-D-18-05657 [pii]
AID - 10.1097/MD.0000000000013906 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Jan;98(2):e13906. doi: 10.1097/MD.0000000000013906.